Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Stock Has Average Price Target of $128.54 According to Brokerages

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has been given a consensus rating of “Buy” by the sixteen ratings firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, thirteen have issued a buy rating and two have issued a strong buy rating on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $128.77.

A number of brokerages have recently issued reports on DNTH. Roth Capital assumed coverage on shares of Dianthus Therapeutics in a research note on Tuesday, October 27th. They issued a “buy” rating and a $113.00 price objective for the company. Truist Financial boosted their price objective on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Thursday, October 15th. JPMorgan Chase & Co. began coverage on shares of Dianthus Therapeutics in a research note on Friday, September 11th. They set an “overweight” rating and a $135.00 price target on the stock. Finally, Wedbush increased their price target on shares of Dianthus Therapeutics from $105.00 to $122.00 and gave the company an “outperform” rating in a report on Wednesday, August 5th.

Dianthus Therapeutics Stock Up 3.6%

Shares of Dianthus Therapeutics stock opened at $86.03 on Monday. Dianthus Therapeutics has a twelve month low of $34.29 and a twelve month high of $117.88. The firm has a market cap of $4.71 billion, a PE ratio of -21.56 and a beta of 1.47. The business has a 50-day moving average price of $90.05 and a 200 day moving average price of $85.57.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Wednesday, November 4th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.13. The company had revenue of $1.21 million during the quarter, compared to analysts’ expectations of $0.46 million. Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. On average, sell-side analysts expect that Dianthus Therapeutics will post -3.81 EPS for the current year.

Insider Buying and Selling at Dianthus Therapeutics

In other Dianthus Therapeutics news, Director Simon Read sold 2,778 shares of the business’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $117.55, for a total transaction of $326,553.90. Following the completion of the sale, the director owned 2,778 shares in the company, valued at $326,553.90. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Edward Carr sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $101.38, for a total value of $2,027,600.00. Following the completion of the transaction, the chief accounting officer directly owned 20,000 shares in the company, valued at $2,027,600. The trade was a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 72,596 shares of company stock worth $7,748,340 in the last three months. 3.02% of the stock is owned by company insiders.

Institutional Investors Weigh In On Dianthus Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new position in Dianthus Therapeutics during the second quarter valued at approximately $401,990,000. Wellington Management Group LLP lifted its position in shares of Dianthus Therapeutics by 24.4% in the 2nd quarter. Wellington Management Group LLP now owns 3,229,882 shares of the company’s stock worth $314,849,000 after buying an additional 634,099 shares during the last quarter. Jennison Associates LLC acquired a new stake in shares of Dianthus Therapeutics in the first quarter worth $40,713,000. Assenagon Asset Management S.A. boosted its holdings in Dianthus Therapeutics by 160.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 732,246 shares of the company’s stock valued at $64,474,000 after purchasing an additional 451,597 shares during the period. Finally, Spruce Street Capital LP bought a new stake in shares of Dianthus Therapeutics during the 2nd quarter valued at $34,587,464. 47.53% of the stock is owned by institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for autoimmune and inflammatory diseases. The company’s research centers on the complement system, an important part of the immune response that can contribute to tissue damage and disease when improperly activated.

Dianthus’ lead product candidate, DNTH103, is an investigational, fully human monoclonal antibody designed to selectively inhibit C1s, a key protein in the classical complement pathway.